LG Life Science

LG Life Sciences, now the Life Sciences division of LG Chem, is a prominent South Korean pharmaceutical company specializing in the development and commercialization of diverse therapeutic products. The company achieved a historic milestone in 2003 when its antibiotic Factive (gemifloxacin) became the first South Korean drug to receive FDA approval. Its current portfolio is anchored by the blockbuster diabetes treatment Zemiglo (gemigliptin) and a robust range of biologics, including growth hormones, vaccines, and fertility treatments. LG Life Sciences maintains a strong global presence, supplying essential vaccines to international organizations like UNICEF and PAHO. The company is aggressively advancing its R&D pipeline with a focus on oncology, immunology, and metabolic diseases, recently bolstered by the acquisition of AVEO Oncology.